Versant Ventures has launched Cimeio Therapeutics, a biotech startup with technology that can shield transplanted stem cells or cell therapies. Shielding these cells enables them to be dosed alongside an immunotherapy—an approach that is not currently done because the therapies don't discriminate between diseased cells and transplanted ones.
We've made significant progress on interoperability from initiatives like the Trusted Exchange Framework and Common Agreement to health tech vendors and healthcare providers working to make patient data more accessible.
But is the interoperability glass half full or half empty? What progress have we made and what challenges remain?
This webinarsponsored by Surescripts will take stock of the past two years since the Covid-19 pandemic started and explore the progress we've made.
By Hannah Recht, Kaiser Health News Friday, April 15, 2022 6:54 PM
Large swaths of the country had no test-to-treat pharmacies or health centers listed as of April 14. And the website of the largest participant, CVS, has significant technical issues that make booking an appointment difficult.
With the information contained in a simple 30-second voice sample, providers can help patients get ahead of future health issues and prescribe or adjust treatment plans as needed.
Versant Ventures has launched Cimeio Therapeutics, a biotech startup with technology that can shield transplanted stem cells or cell therapies. Shielding these cells enables them to be dosed alongside an immunotherapy—an approach that is not currently done because the therapies don't discriminate between diseased cells and transplanted ones.
By Michael Schroeder Friday, April 15, 2022 12:55 PM
The survey, released Thursday by National Nurses United, polled 2,575 registered nurses. Hospital RNs also reported that their hospitals are still not adequately prepared for a Covid-19 surge.
No comments